Company intelligence
Molekule Consulting
Strategic Intelligence that De-risks Capital and Commercial Decisions.
About Molekule Consulting
Molekule Consulting is the specialized intelligence partner for biopharma leaders who need to validate reality before committing capital. THE REALITY GAP Data rooms and public filings often present a sanitized view of an asset. We collect what is missing. We don't rely on assumptions; we stress-test your strategy against the ground truth of the clinical and commercial landscape. Our job is to find the hidden constraints—whether Regulatory, CMC, or Market Access—that impact the Net Present Value (NPV) of your asset. CORE CAPABILITIES Clinical & Development Intel We see past the press release. We validate investigator sentiment, enrollment velocity, and data integrity risks to give you a true read on competitor timelines. Commercial & Market Access We map the real payer landscape and formulary threats, distinguishing between a competitor's "announced" launch strategy and their actual ability to execute in the field. Lifecycle Defense (LoE) We model counter-strategies for Loss of Exclusivity events and generic/biosimilar entry, helping you structure a defense before erosion begins. Strategic War-Gaming We simulate Launch vs. Counter-Launch scenarios to force leadership to confront the consequences of competitor interference. OUR STANDARD We do not speculate. We provide the clarity required to make high-stakes decisions. Note: To protect our collection network, we do not publish client lists. Please direct inquiries to the contact below. Contact: info@molekuleconsulting.com
Verified activity
Signals from Molekule Consulting
5 published signals
Legal & Regulatory
Molekule Consulting notes that vHOT got more expensive as an accelerated-approval handle than any model on the Street is showing this morning.
Reported by Molekule Consulting
Research & Knowledge
Molekule Consulting highlights that it cannot predict blinded trial data and that primary intelligence should stress-test assumptions before the headline.
Reported by David Alderman
Research & Knowledge
Molekule Consulting published new data in Pediatrics suggesting that children ages 8 to 11 with severe obesity receive off-label GLP-1 therapy, with annual GLP-1 prescribing rising from 0.03% in 2019 to 9.3% in 2026.
Reported by David Alderman
Capital & Finance
Molekule Consulting notes that Merida Biosciences' lead program is still in Phase 1.
Reported by David Alderman
Capital & Finance
Molekule Consulting notes that Merida Biosciences received a valuation signal of up to $2.875B following its $121M Series A funding round.
Reported by David Alderman